ISPOR - Assessing The Likely Cost-Utility Of Alemtuzumab Versus Rabbit Anti-Thymocte Globulin As Induction Therapy For High-Risk Kidney Transplant Recipients

Full Text

Assessing The Likely Cost-Utility Of Alemtuzumab Versus Rabbit Anti-Thymocte Globulin As Induction Therapy For High-Risk Kidney Transplant Recipients

Abstract

Authors

A Tung E. Devine L. Garrison

Back to Volume 17, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now